

INSTITUTO DE INVESTIGACIÓN SANITARIA
SANTIAGO DE COMPOSTELA

A stylized lowercase letter 'i' composed of several overlapping, semi-transparent shapes in shades of green, yellow, and brown, resembling a mountain range or a cluster of cells. It is positioned to the left of the main 'ididis' text.

ididis

ANNUAL REPORT 2025



EDITION AND PRODUCTION

Scientific-Technical Coordination of the Health
Research Institute of Santiago de Compostela

José Ramón Castro Ruibal

Technical Management

Yolanda Liste Martínez

Technical Management

Iria Louzao Pernas

Technical Management

María Rodríguez Carlín


Technical Management

APPROVAL

Direction Board of the Institute
at the meeting on 25 May, 2026.



ANNUAL REPORT 2025



HEALTH RESEARCH INSTITUTE. SANTIAGO DE COMPOSTELA



idiis

É un pracer presentar un ano máis a Memoria Científica do IDIS, un documento que recolle de forma detallada os nosos indicadores de actividade desenvolvida en 2025. Esta memoria non só mostra os resultados obtidos, senón que tamén reflicte o compromiso da nosa institución coa excelencia científica e a innovación no ámbito da saúde.

O último ano estivo marcado por logros significativos nas nosas principais unidades de investigación, que permitiron consolidar proxectos estratéxicos e abrir novas oportunidades. Neste contexto, resulta especialmente destacable o recoñecemento do CIMUS como Unidade de Excelencia María de Maeztu, outorgado polo Ministerio de Ciencia, Innovación e Universidades. Este logro representa unha gran satisfacción para o noso Instituto, non só polo prestixio que leva consigo, senón tamén porque gran parte do seu persoal investigador está vinculado coa nosa institución, reforzando así o impacto e a proxección da nosa actividade científica.

Nun contorno cada vez máis esixente e competitivo, o noso Instituto logrou consolidarse como unha entidade de referencia, liderando en 2025 entre os institutos de investigación sanitaria acreditados polo ISCIII a captación de talento a través das convocatorias da Acción Estratéxica en Saúde. A incorporación de persoal investigador cualificado constitúe un motor fundamental para o noso crecemento e para o incremento da capacidade de xeración de coñecemento. Froito deste impulso, en 2025

M^a Luz Couce Pico

*Directora Científica
Scientific Director*

acudamos un total de 1.163 publicacións científicas en revistas indexadas, o que supón un incremento do 6,6 % respecto ao ano anterior, consolidando así unha tendencia sostida de crecemento na nosa produción científica.

A captación de recursos continúa sendo, un ano máis, un motivo de especial orgullo para o noso Instituto. Durante 2025 logramos superar os **50 millóns de euros** en financiamento, un fito que reflicte **a solidez da nosa estrutura investigadora e a competitividade dos nosos grupos**, non só no acceso a convocatorias tanto nacionais como internacionais, senón tamén na capacidade para xerar financiamento a través de actividades coa industria. Este resultado pon de manifesto non só a calidade científica dos nosos proxectos, senón tamén a capacidade do noso centro para identificar oportunidades e xerar propostas de alto nivel. En conxunto, estes logros reforzan a nosa traxectoria de crecemento na captación de recursos.

Esta progresión, impulsada tanto polo desenvolvemento institucional como pola excelencia dos nosos grupos de investigación, pon de manifesto a necesidade de seguir avanzando no fortalecemento das

nosas infraestruturas. Neste sentido, resulta cada vez máis evidente a importancia de contar con novos espazos de investigación que permitan dar resposta ás demandas futuras da nosa actividade científica. Por iso, continuaremos traballando con determinación no desenvolvemento dun novo espazo que favoreza a investigación de excelencia e a colaboración de todas as persoas que forman parte do Instituto.

Os logros recollidos nesta memoria son froito do traballo coordinado dun equipo cualificado e comprometido, cuxo esforzo contribuíu a consolidar o noso Instituto como un referente en investigación biomédica e sanitaria. Estes avances reforzan, ademais, o noso compromiso coa difusión do coñecemento, promovendo unha comunicación científica accesible, rigorosa e orientada á sociedade.

Miramos ao futuro con responsabilidade e determinación, conscientes dos desafíos que formula o ámbito da investigación sanitaria, pero tamén das oportunidades que ofrece. Reafirmamos o noso compromiso coa excelencia, a ética, a innovación e o servizo á sociedade, coa convicción de que a ciencia é fundamental para o progreso e o benestar colectivo.

It is a pleasure to present once again the IDIS Scientific Report, a document that provides a detailed overview of the indicators corresponding to the activities carried out in 2025. This report not only showcases the results achieved, but also reflects our institution's commitment to scientific excellence and innovation in the field of health.

The past year has been marked by significant achievements across our main research units, enabling us to consolidate strategic projects and open up new opportunities. In this context, special mention should be made of the recognition of CIMUS as a María de Maeztu Unit of Excellence, awarded by the Ministry of Science, Innovation and Universities. This achievement represents a great source of satisfaction for our Institute, not only because of the prestige it entails, but also because a large part of its research staff is linked to our institution, thereby reinforcing the impact and visibility of our scientific activity.

In an increasingly demanding and competitive environment, our Institute has succeeded in consolidating its position as a leading institution,

ranking first among the health research institutes accredited by ISCIII in 2025 in terms of talent recruitment through the Strategic Action in Health calls. The incorporation of highly qualified research personnel constitutes a key driver of our growth and of our capacity to generate knowledge. As a result of this momentum, in 2025 we reached a total of 1,163 scientific publications in indexed journals, representing a 6.6% increase compared to the previous year and consolidating a sustained upward trend in our scientific output.

Once again, fundraising and resource acquisition continue to be a particular source of pride for our Institute. During 2025, we succeeded in surpassing **€50 million in funding**, a *milestone that reflects the strength of our research structure and the competitiveness of our groups*, not only in securing national and international grants, but also in generating funding through collaborations with industry. This result demonstrates not only the scientific quality of our projects, but also our institution's ability to identify opportunities and develop high-level proposals. Altogether, these achievements reinforce our growth trajectory in attracting resources.

Os logros recollidos
nesta memoria
son **froito do traballo
coordinado dun equipo
cualificado e comprometido**,
cuxo esforzo contribuíu a
consolidar o noso Instituto
como un referente en
investigación biomédica
e sanitaria.



The achievements presented in this report are **the result of the coordinated efforts of a highly qualified and committed team**, whose dedication has contributed to consolidating our Institute as a benchmark in biomedical and health research.

This progress, driven both by institutional development and by the excellence of our research groups, highlights the need to continue strengthening our infrastructure. In this regard, the importance of having new research spaces capable of meeting the future demands of our scientific activity is becoming increasingly evident. For this reason, we will continue working with determination towards the development of a new environment that fosters research excellence and collaboration among all those who are part of the Institute.

The achievements presented in this report are the result of the coordinated efforts of a highly qualified and committed team, whose dedication has contributed to consolidating our Institute as a benchmark in biomedical and health research. These advances also reinforce our commitment to the dissemination of knowledge, promoting scientific communication that is accessible, rigorous, and society-oriented.

We look to the future with responsibility and determination, fully aware of the challenges posed by the field of health research, but also of the opportunities it offers. We reaffirm our commitment to excellence, ethics, innovation, and service to society, convinced that science is a fundamental pillar for progress and collective well-being.

HEALTH RESEARCH INSTITUTE. SANTIAGO DE COMPOSTELA

Summary

ANNUAL REPORT 2025

01
Executive
summary
12

02
Structure
17

03
Scientific
results
29



04
Funding
37

05
Innovation
and transfer
53

06
Platforms
63

07
Training and
dissemination
79

08
Strategic
alliances
89

09
Areas
95



Executive summary

1

Mission, vision, values

The **Health Research Institute of Santiago de Compostela (IDIS)** is a biomedical research center of marked translational character that takes advantage of the synergies of the **University Clinical Hospital of Santiago de Compostela (CHUS)** and the **University of Santiago de Compostela (USC)** to promote and encourage excellent research, scientific and technological knowledge and its subsequent transfer to the productive sector, as well as teaching and training, focused on a clear objective: to improve the people's health.



1

MISSION

We are a translational biomedical research center that involves professionals with a sole objective: **to improve the health of citizens.**



2

VISION

To consolidate our position as a **research center of reference, at both national and international level**, in the innovative approach of the great challenges of the population in the healthcare field, promoting at all times the transfer of high impact results to society.



3

VALUES

- Integration and collaboration.
- Communication and transparency.
- Leadership and research excellence.
- Innovation and result transfer orientation.
- Responsibility to and for society.

01. EXECUTIVE SUMMARY

Key Performance Indicators (KPI)




TOTAL FUNDING 2025

50.896.550,48 €

● COMPETITIVE FUNDING _____ **35.397.640,57 €**



PROJECTS
25.411.167,18 €



HR COMPETITIVE
CONTRACTS
9.828.928,39 €



MOBILITY GRANTS
157.545,00 €

● NON COMPETITIVE FUNDING
15.498.909,91 €




CLINICAL STUDIES

8.046.365,46 €



CONTRACTS AND PROVISION OF SERVICES

6.953.157,43 €



DONATIONS

485.826,68 €



TRANSFER

13.560,34 €



PUBLICATIONS



PhD THESES



REQUESTED PATENTS



GRANTED PATENTS



ACTIVE SPIN OFF



SPIN OFF CREATED





idis

HEALTH RESEARCH INSTITUTE, SANTIAGO DE COMPOSTELA




Structure

ANNUAL REPORT 2025



2



BOARD OF DIRECTORS

President

Antonio Gómez Caamaño

Vice-President

Antonio López-Díaz

Chairs

Pilar Bermejo Barrera
Ángel María Carracedo Álvarez
José María Carreira Villamor
Juan Enrique Domínguez Muñoz
Ángel Facio Villanueva
Antonio Fernández Campa
José Ramón González Juanatey
José Luis Labandeira García
M^a Luz Couce Pico (without vote)
Isabel Lista García (without vote)

02. STRUCTURE

External Scientific Committee

Ángeles Almeida Parra
Melchor Álvarez de Mon Soto
María del Carmen Ayuso García
Joan Comella Carnicé
Encarnación Guillén Navarro
María Rosario Luquin Piudo
Antonio Vidal Puig

Internal Scientific Committee

President
M^a Luz Couce Pico

Secretary
José Ramón Castro Ruibal

Non-scientific actors

Afundación Obra Social
ABANCA
Consello Social USC
Asociación Española
Contra el Cáncer - AECC
Federación Galega de
Enfermidades Raras e
Crónicas - FEGEREC
Financiera Maderera S.A
FINSA
Grupo FRINSA del
Noroeste

Ana Alonso Pérez
José Víctor Álvarez González
Ángel María Carracedo Álvarez
Miriam Cebey López
Sergio Cinza Sanjurjo
Manuel Collado Rodríguez
Anxo Fernández Ferreiro
José Ramón González Juanatey
Francisco Gude Sampedro
José Luis Labandeira García
Isabel Lista García
Rafael López López
Mabel Loza García
Miguel Ángel Martínez Olmos
Federico Martínón Torres
Alberto Ruano Raviña
Mabel Sampedro Parada
Luisa María Seoane Camino
Tomás Sobrino Moreiras
Ana Vega Gliemmo
Sandra Vidal Martínez

Quality Commission

President
Miriam Cebey López

Secretary
Iria Louzao Pernas

M^a Mar Lale Candal
Isabel Lista García
Mabel Sampedro Parada

Innovation and Transfer Commission

President
Anxo Fernández Ferreiro

Secretary
José Ramón Castro Ruibal

José Manuel Brea Floriani
Cristina Fernández Pérez
María de la Fuente Freire
Luis Ángel León Mateos
Adrián Mosquera Orgueira
Moisés Rodríguez Mañero
Mabel Sampedro Parada

Training Commission

President
Manuel Collado Rodríguez

Secretary
José Ramón Castro Ruibal

Jorge Barbazán García
Sonia Eiras Penas
Ana Estany Gestal
Anxo Fernández Ferreiro
Cristina Fernández Pérez
Francisco Gude Sampedro
Ana Igea Fernández
M^a del Carmen Rivas Vázquez
Anxo Vidal Figueroa

Scientific - technical coordination

José Ramón Castro Ruibal
Yolanda María Liste Martínez
Iria María Louzao Pernas
María Rodríguez Carlin

02. STRUCTURE

Scientific structure



1486
People

868 ♀
618 ♂

1447

Research and
technical staff


837 ♀
610 ♂

39

Transversal

31 ♀
8 ♂

Oncology

 **285**



GROUPS
21

Genetics and
Systems Biology

 **201**



GROUPS
15

Endocrinology,
Nutrition and
Metabolism

 **165**



GROUPS
18

Areas
7

GROUPS
113

220

Research staff fully or partially funded through competitive calls and research networks

Neurosciences



253



GROUPS
21

Platforms and
Methodology



185



GROUPS
15

Cardiovascular



174



GROUPS
12

Infectology,
Inflammation and
Vaccines



184




GROUPS
11

Research **groups**

GROUPS
45

Consolidated

 769 | 446 ♀
323 ♂

GROUPS
50


Emerging

 494 | 298 ♀
196 ♂

GROUPS
18

Clinical Associate


 184 | 93 ♀
91 ♂




Woman



Man




IDIS members evolution



TOTAL 2025

1486







idis

HEALTH RESEARCH INSTITUTE, SANTIAGO DE COMPOSTELA

Scientific results

ANNUAL REPORT 2025

A decorative graphic on a blue background featuring overlapping circles and squares of varying shades of blue. A large, semi-transparent circle in the lower half contains a large, bold number '3'.

3


03. SCIENTIFIC RESULTS




TOTAL
PUBLISHED
ARTICLES 2025
1163

The Institute has published **1.163 original scientific articles, editorials and reviews** in international journals indexed in the Journal Citation Report with a **cumulative impact factor of 6445.7 points** and **average impact factor of 5.5 points.**

Number of published articles per year







Number of **articles published** **in journals ranked in** the first decile




03. SCIENTIFIC RESULTS

Number of **publications** and **% of the total** in 2025



Number of **published articles per year**,
by journal quartile




Collaborations

559

International collaboration

367

IDIS collaboration





idis

HEALTH RESEARCH INSTITUTE, SANTIAGO DE COMPOSTELA

Funding


ANNUAL REPORT 2025


4



TOTAL FUNDING 2025

50.896.550,48 €





04. FUNDING


COMPETITIVE FUNDING 2025

35.397.640,57 €


(Projects, hr, mobility)

Projects

6.324.007,20 €



14.691.574,42 €




4.395.585,56 €





TOTAL
PROJECTS 2025
115

PROJECT FUNDING 2025
25.411.167,18 €









Human resources




HR COMPETITIVE
CONTRACTS 2025

9.828.928,39 €

AGENCY	CONCEPT	NUMBER	AMOUNT
	GAIN Postdoctoral Grant	6	1.146.733,74 €
	GAIN Predoctoral Grant	19	2.053.717,88 €
 Instituto de Salud Carlos III	PFIS	4	418.934,00 €
	iPFIS	1	89.900,00 €
	Rio Hortega	5	325.000,00 €
	Sara Borrell	3	285.000,00 €
	Miguel Servet	5	1.543.000,00 €
	Juan Rodés	3	738.300,00 €
	Intensification	2	90.000,00 €
	Ramón y Cajal	3	785.655,87 €
 AGENCIA ESTATAL DE INVESTIGACIÓN	Juan de la Cierva	2	163.874,88 €
	Predoctoral	3	382.391,29 €
	Technical support staff	1	46.800,00 €
	Postdoctoral	3	336.168,00 €
	Predoctoral	6	502.937,10 €
	Platform technician	1	87.500,00 €
 UNIVERSIDADE DE SANTIAGO DE COMPOSTELA	Predoctoral	6	300.759,51 €
 MINISTERIO DE CIENCIA, INNOVACIÓN Y UNIVERSIDADES	FPU	4	532.256,12 €

HR competitive contract evolution





Mobility

Total

6

**MOBILITY FUNDING
2025**

157.545,00 €


04. FUNDING

NON COMPETITIVE FUNDING 2025

15.498.909,91 €

(Studies, Contracts and Provision of Services, Transfer, Donations)

Clinical studies





Studies

Total
396

CLINICAL STUDIES RAISED
8.046.365,46 €

198

Clinical trials

7.550.935,46 €

198

Observational studies

495.430 €

Contracts and provision of services




TOTAL
CONTRACTS 2025

289

RAISED 2025

6.953.157,43 €



Donations




TOTAL
DONATIONS 2025

150

RAISED 2025

485.826,68 €





Transfer

Total

3

RAISED 2025

13.560,34 €



idis

HEALTH RESEARCH INSTITUTE, SANTIAGO DE COMPOSTELA



Innovation and transfer

ANNUAL REPORT 2025



05. INNOVATION AND TRANSFER

**Transfer acceleration
through public
funding and
private investment**

ITEMAS network

The Innovation Platform in Medical and Healthcare Technologies (ITEMAS) is a support structure for healthcare innovation promoted by the Carlos III Health Institute (ISCIII), whose objective is to facilitate the innovative ideas of healthcare professionals to generate value for the system, through favoring the transfer of technology, the culture of innovation and communication with the rest of society.

ITEMAS' main goal is the creation of Innovation Support Units (UAI) in hospitals and biomedical research institutes, including IDIS.

**Disseminating
our Research**

BioINCUBATECH

BioIncubaTech is the High Technology Incubator for the promotion of innovation and biotechnology transfer in the field of health and food technologies to micro-SMEs. BioIncubaTech belongs to "High Technology Incubators for the promotion of innovation and technology transfer to micro-SMEs" Project, aimed to modernize the regional productive fabric. These Incubators are created as traction instruments aligned with the objectives of the EU 2020 and Horizon 2020 Strategy and will promote interregional cooperation, as well as collaboration between public and private sector agents at international level.

IDIS collaborates since the beginning of this proposal and helped to create the project. We have 2 incubated projects.



REQUESTED PATENTS



GRANTED PATENTS



SPIN OFF CREATED



ACTIVE SPIN OFF

2
REQUESTED INTELLECTUAL PROPERTY

8
GRANTED INTELLECTUAL PROPERTY

1
LICENSES 2025

12
ACTIVE LICENSES

1
DISTINCTIVE SIGN /TRADEMARKS 2025

9
ACTIVE DISTINCTIVE SIGN /TRADEMARKS

05. INNOVATION AND TRANSFER



Active
Spin off

XUNTOS. ATENCION
PSICOLOGICA Y
PSIQUIATRICA S.L.

XUNTOS *Atención Psicológica
y Psiquiátrica, S.L.*

The clinic employs a multidisciplinary team comprised of professionals trained at prestigious national and international centers, from the USC and the clinical field.

Founded in 2013.



Active
Spin off

NASASBIOTECH S.L.

 **NASASBIOTECH**

Development of novel clinical solutions in liquid biopsy to improve the diagnosis, prognosis and treatment of cancer.

Founded in 2014.



Active
Spin off

QUBIOTECH, HEALTH
INTELLIGENCE, S.L.

QUBIO 
tech

Automated extraction of biomarkers in neuroimaging.

Founded in 2014.



Active
Spin off

LINCBIOTECH, S.L.

 **Lincbiotech**

Innovative solutions for an enhanced clinical management of patients who suffer from highly prevalent neurological diseases such as stroke and Alzheimer's disease.

Founded in 2017.



BFLOW S.L.



Complete microfluidic and organ-on-a-chip solutions for Pharma & Biotech.

Founded in 2020.



FLOWRESERVE S.L.



Its technology allows the prevention of cardiovascular diseases in very early stages, avoiding later complications as treatment is given on time.

Founded in 2020.



LIBERA BIO, S.L.



Libera Bio is dedicated to developing a new class of therapeutics addressing intracellular disease targets, with an initial focus on cancer.

Founded in 2020.



SMART VITAMINS S.L.



Its research drives the creation of a new generation of drugs, medical devices, and cosmetic formulations designed for specific purposes.

Founded in 2020.

05. INNOVATION AND TRANSFER



CELTARYS RESEARCH S.L.



Celtarys develops and commercializes new chemical tools to spread the use of fluorescence-based methods in drug Discovery.

Founded in 2021.



VENTILATIO LAB S.L.



Ventilatio Lab uses computational fluid dynamics (CFD) technology to design an intelligent natural ventilation protocol and minimize radon concentration.

Founded in 2022.



DIVERSA
TECHNOLOGIES S.L.



DIVERSA offers a reliable and versatile drug delivery technology ready for research and industrial use.

Founded in 2022.



GAZELLA BIOTECH S.L.



It develops advanced therapies for the treatment of metabolic diseases through innovative approaches.

Founded in 2024.



Spin off Created

ALBOR BIOTECH S.L.
Founded in 2025.



Spin off Created

LYREA BIOTECH S.L.
Founded in 2025.

Economic return from
knowledge transfer activities



LICENSES

13.560,34 €



CONTRACTS

369.877,00 €

Inventions

TITLE	TYPE OF INVENTION
Cystanalyser	Process innovation
LipoDDX	Product and process innovation
GALCOVID	Product and process innovation
NEMECUM	Product and process innovation
NUTRISEN	Product and process innovation
CHRONIBERIA	Product and process innovation
PK-PDRUGS	Product innovation



idis

HEALTH RESEARCH INSTITUTE, SANTIAGO DE COMPOSTELA



Platforms

ANNUAL REPORT 2025



6

06. PLATFORMS



GENOMICS

- Genomics
- Direct Digital Molecular Detection (Nanostring)
- Transcriptomics
- Bioinformatics
- Epigenomics
- Single Cell
- Digital PCR



PROTEOMICS



TRANSVERSAL RESEARCH METHODOLOGY UNIT (UTAMI)



PHARMACOKINETICS (PK-PDRUGS)



EXPERIMENTAL SURGERY UNIT



INTEGRATED UNIT OF BIOBANK & BIOMODELS



CELL BIOLOGY

- Platform SP-IRIS /Exoview
- Flow Cytometry
- Liquid Biopsy Unit
- Confocal Microscopy



IMAGING

- Radiomics Unit
- Magnetic Resonance imaging
- Multiphoton Microscope
- Ecocardio



BIOMARKERS PLATFORM IN BIOLOGICAL FLUIDS (SIMOA HD-X)



ARTIFICIAL INTELLIGENCE



BODY COMPOSITION



Genomics

Beatriz Sobrino Rey

beatriz.sobrino.rey@sergas.es

The application of the most modern technologies of genetic or pharmaceutical analysis require, in addition to the necessary equipment, expert knowledge for the adequate interpretation of the results obtained from them. Before starting the process it is essential to have adequate general knowledge of the field and specific knowledge of the capacities, limitations and alternatives in each particular case.



Direct Digital Molecular Detection (Nanostring)

Alberto Gómez Carballa

alberto.gomez.carballa@sergas.es

The nCounter® Assay System allows hundreds of mRNAs, miRNAs, SNVs, CNVs or proteins to be analyzed directly by direct digital molecular detection, in a single reaction in the absence of enzymes (no reverse transcription or amplification). It is a system of high sensitivity and reproducibility, with great multiplexing capacity (up to 800 genes in the same reaction). The technique not only reduces the number of necessary reactions, but also saves the amount of RNA/DNA that is used. required for the test.



Transcriptomics

Isabel Ferreirós Vidal

Isabel.Ferreiros.Vidal@sergas.es

This platform is equipped with an Illumina NextSeq 2000 System, which provides high-throughput sequencing with enhanced flexibility and scalability to accommodate diverse experimental demands and production workflows. The system supports a broad range of genomic applications, enabling projects with varied sequencing objectives, including: » Whole-transcriptome sequencing. » Human exome sequencing. » Targeted gene panel sequencing. » Metagenomic profiling. » Single-cell RNA sequencing. » Immune repertoire sequencing.



Bioinformatics

Jorge Amigo Lechuga

jorge.amigo@usc.es

The Bioinformatics Platform is made up of a multidisciplinary team with experience in handling data obtained from omics technologies and in translational medicine. Its purpose is to provide both basic and clinical researchers with technological support and advice on the numerical analysis and processing of large volumes of data from different areas of the life sciences, applying techniques from both the fields of biology and chemistry, physics or mathematics, to obtain new knowledge.



Epigenomics

Ana Belén Crujeiras Martínez

Ángel Díaz Lagares

anabelencrujeiras@hotmail.com

angel.diaz.lagares@sergas.es

Epigenomics contributes to solving multiple biological processes related to the development of diseases and is particularly useful in the field of personalized medicine. The Epigenomics Unit, created in collaboration between the Endocrinology and Nutrition area and the Oncology area of IDIS and in consortium between FIDIS and the CIBER Physiopathology of Obesity and Nutrition (CIBERObn), aims to provide help and support to research groups and industry at a national and international level in carrying out epigenomic studies, at the level of specific genes or the epigenome.



Single Cell

Isabel Ferreirós Vidal

Isabel.Ferreiros.Vidal@sergas.es

The Chromium X technology from 10x Genomics enables the analysis of cellular complexity from multiple omic perspectives, including transcriptomics, proteomics, and epigenomics, at single-cell resolution. The integration of information from these distinct molecular layers across thousands of cells per sample substantially enhances the analytical power of experiments, providing a more comprehensive and high-resolution characterization of complex biological systems.



Digital PCR

Isabel Ferreirós Vidal

Isabel.Ferreiros.Vidal@sergas.es

The QuantStudio Absolute Q digital PCR system is an ideal solution for any application requiring high sensitivity, precision, and accuracy: » Quantification of low-concentration targets (viruses, liquid biopsies). » Genotyping of SNPs and gene mutations. » Absolute quantification of genetic material. » Copy number variation analysis. » Gene expression analysis.



Proteomics

Susana B. Bravo López

Susana.Belen.Bravo.Lopez@sergas.es

The Proteomics platform was created with the purpose of boosting research, providing support and offering researchers a comprehensive infrastructure in the field of proteomics managed by highly specialized staff. It has cutting-edge equipment used to conduct complete proteome characterization studies, but also differential expression analysis studies.



Pharmacokinetics

Anxo Fernández Ferreiro

anxordes@gmail.com

The unit (PK-PDrugs) coordinated from the Research and Innovation Unit of the Pharmacy Service of Santiago de Compostela, is committed to the most sophisticated analytical technologies focused on the determination of drugs and metabolites in the different fields of biomedical research.



Integrated Unit of Biobank and Biomodels

**Máximo Fraga; Rodolfo Gómez;
Anxo Vidal**

*biobanco.apa.santiago@sergas.es
bbi3d@mpgroup.es cebega@usc.es
lydia.fraga.fontoira@sergas.es*

With the aim of accelerating translational research by offering a comprehensive solution to the research community, currently the following Research Support Platforms dependent on SERGAS and the University of Santiago de Compostela (USC) are constituted as a unicentric integrated unit BIOBANK AND BIOMODELS: » Biobank CHUS - Máximo Fraga » Platform of Biovalidation, Biofabrication and 3D Printing (BBI-3D) - Rodolfo Gómez » Experimental Biomedicine Centre of the University of Santiago de Compostela (CEBEGA) - Anxo Vidal It is a unique structure made up of these three units with the main objective of accelerating translational research. It is precisely the close relationship between the units that sustains its unique value and its potential to offer a broad portfolio of services to the research community.



Transversal Research Methodology Unit (UTAMI)

Ana Estany Gestal

metodologia.idis.santiago@sergas.es

The Research Methodology Transversal Unit (UTAMI) is a support unit specialized in research methodology, biostatistics, bioethics and regulation. UTAMI is coordinated from the Research Methodology Unit of IDIS Foundation, with the aim of promoting competitive research by offering research staff a highly qualified service, aimed at promoting three fundamental aspects of research: scientific publications, research projects and doctoral theses.



Experimental Surgery Unit

María Victoria Valiño Cultelli

animalario@idisantiago.es

The Experimental Surgery Unit provides support in biomedical research with several animal models for IDIS research groups, in strictly controlled sanitary and environmental conditions. The Experimental Surgery Unit is accredited by the Ministry of Rural Environment of the Xunta de Galicia. It has rat and mouse housing facilities, surgery rooms and specialized qualified personnel, in accordance with current regulations. It also has an Ethics Committee on Animal Experimentation. It holds the corresponding accreditation as an Authorized Body to carry out the evaluation of projects from a scientific or educational point of view. It is responsible for advice on issues related to animal welfare, review of internal operational processes, issuance of reports and monitoring of projects. Its objectives are to promote research, and to develop and implement biomedical training, providing professionals with the necessary resources for the development of these initiatives.



Platform SP-IRIS/ExoView

María Pardo Pérez

Maria.Pardo.Perez@sergas.es

The ExoView platform is based on single particle interferometric reflectance imaging sensor SP-IRIS technology providing a compact multi-parameter solution for the capture and analysis of Extracellular Vesicles (EVs)/exosomes, functionalized nanoparticles and viruses. It allows capturing EVs, measuring size (nm) by means of visible light interference, and quantifying by fluorescence the number of vesicles with specific antibodies providing protein profile of both membrane and intravesicular proteins in functionalized chips using very little sample in any biological fluid (plasma, serum, urine, CSF, etc) and secretomes. The SP-IRIS/Exoview platform is a member of the Grupo Español en Innovación e Investigación en Vesículas Extracelulares (GEIVEX) and a recipient of both the GEIVEX mobility and International MOOVE mobility grants. Training capacities: we are participating as experts in the Specialization Course on Extracellular Vesicles at Universidad Francisco Victoria, Madrid.



Flow cytometry

Pablo Hervella Lorenzo

Pablo.Hervella.Lorenzo@sergas.es

It is a technique of cell analysis that allows to measure the characteristics of light scattering and cell fluorescence when those cells pass through a light beam. The platform's main aims are:

- » To advise users on the principles and applications of flow cytometry analysis and cell sorting.
- » To develop, optimize and perform new analytical applications demanded by the users.
- » To do cellular isolation through cell sorting.
- » To quantify different soluble cytokines using multiplex tests.



Liquid biopsy unit

Laura Muinelo Romay

laura.muinelo.romay@sergas.es

The Liquid Biopsy Analysis Unit is a laboratory specialized in the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and other tumor elements present in different biological fluids such as blood, saliva, pleural fluid or cerebrospinal fluid, among others. The unit, created in 2012, provides services to different national and international clinical and research groups for the study of liquid biopsy. Interest in the study of tumor material present in biological fluids has increased exponentially in the last decade, mainly because it is the least invasive and the most dynamic strategy for characterizing tumors.



Confocal microscopy

Marta Picado Barreiro

Marta.Picado.Barreiro@sergas.es

The confocal scanning microscope is well-known for its ability to perform optical sectioning: a thin plane or section within a thick turbid medium is non-invasively imaged with high resolution and contrast. Nuclear, cellular and morphologic detail is imaged in living intact tissue without having to excise physically and prepare thin sections or cultures. » The services include the infrastructure and specialised staff to perform analysis as... » 3D imaging reconstruction. » Multiple labeling. » Colocalization. » In vivo fluorescence imaging.



Body Composition

Marcos Couselo Carreira

mccarr@hotmail.es

The Body Composition and Metabolic Checkup Platform was born within the Endocrinology and Nutrition Service of CHUS with the aim of providing scientific, medical and technological support in the field of body composition analysis at different levels: » Scientific studies or clinical trials that require the use of this methodology. » Industries in the food or pharmaceutical sector interested in assessing the effect of their marketed or newly developed products at the level of body composition. » Companies (or individuals) that wish to incorporate “new generation” information in the assessment of the nutritional and health status of their workers. » Sports sector at both an advanced and initial level to monitor fitness and performance improvement.



Radiomics Unit

Pablo Aguiar Fernández

pablo.aguiar.fernandez@sergas.es

Our mission is to bridge the gap between in vitro biomedical research and in vivo preclinical and clinical imaging by providing imaging biomarkers to better understand physiology and pathology in vivo. We offer a core facility that provides dedicated services in medical image processing and quantitative analysis, supporting researchers and clinicians in the evaluation and interpretation of multimodal imaging data (PET, SPECT, CT, and MRI). Our expertise includes kinetic modelling, automated image segmentation, advanced quantitative analysis, and the application of AI to enhance image interpretation, biomarker extraction, and translational research.



Magnetic Resonance imaging

Ramón Iglesias Rey

ramon.iglesias.rey@sergas.es

Magnetic Resonance Imaging is perhaps the most versatile neuroimaging technique that exists nowadays. The use of this platform in its different variants (anatomical, functional, spectroscopy and molecular imaging) allows for a complete, non-invasive (in vivo) and longitudinal monitoring over time of the process associated with neurovascular diseases and others such as plasticity, reorganization and functional recovery in animal models.



Multiphoton microscope

Pablo Hervella Lorenzo

Pablo.Hervella.Lorenzo@sergas.es

The Multi-Photon Microscope is purposebuilt for deep imaging not only in tissue slices and cells but also in clarified tissue, whole organs, and even whole animals. Its working spectral range makes it suitable for 2-photon microscopy applications where the lowest possible phototoxicity is sought and where it is possible to obtain high-quality images at maximum depth, such as in-vivo imaging in small animals such as mice or rats. It is also possible to obtain 2-photon imaging on marker-free samples through secondary and tertiary harmonic imaging.

06. PLATFORMS



EcoCardio

The objective of the unit is to provide professionals in our environment with an effective tool to assess changes in cardiac function in different preclinical models, associated with the pathophysiological process or therapeutic intervention, favoring collaborations and creating synergies between healthcare professionals and researchers. The ECOCARDIO Cardiac Imaging Platform is made up of a multidisciplinary team with extensive experience in the analysis of cardiac function, from SERGAS, IDIS and USC. Non-invasive imaging techniques are a fundamental piece of current cardiovascular medicine, providing accurate diagnoses and providing prognostic information. In addition, they allow monitoring of different pathophysiological processes, often guiding the therapeutic intervention itself.



Biomarkers Platform in Biological Fluids (SIMOA HD-X)

Roberto Carlos Agís Balboa

roberto.carlos.agis.balboa@sergas.es

The SIMOA HD-X Platform, dedicated to the detection of biomarkers in biological fluids, was established in 2023. It uses an automated system that enables the detection of biomarkers in various biological samples (such as plasma, serum, cerebrospinal fluid, urine, and cell lysates) at femtomolar concentrations (1×10^{-15}), through advanced immunodetection technology. This platform facilitates the accurate identification of extremely low biomarker concentrations, the discovery of novel biomarkers, and the development of innovative assays for application in routine clinical practice. The SIMOA equipment is located in a temperature-controlled room equipped with freezers (-80°C and -20°C) and refrigerators (4°C) to ensure proper storage of samples and assay kit reagents. In addition, it is supported by specialized personnel and provides analytical services and assay validation for a range of diseases and biological fluids.



Artificial Intelligence

Adrián Mosquera Orgueira

adrian.mosquera.orgueira@sergas.es

The Artificial Intelligence Platform of the IDIS provides advanced services based on artificial intelligence, computational modeling, and biomedical data analysis. It comprises six specialized areas that support research projects, technological development, and digital transformation initiatives within the healthcare sector.



idis

HEALTH RESEARCH INSTITUTE, SANTIAGO DE COMPOSTELA

Training and dissemination

ANNUAL REPORT 2025



PhD Theses



TOTAL PhD
THESES 2025

95

DEFENDED
BY MALE
RESEARCHERS

36

DEFENDED
BY FEMALE
RESEARCHERS

59

30

WITH
INTERNATIONAL
MENTION (MI)


21

DEFENDED
BY WOMAN

16

DIRECTED,
BY AT LEAST,
ONE WOMAN

PhD Theses evolution



07. TRAINING AND DISSEMINATION

Training activities



TOTAL TRAINING
ACTIVITIES 2025

194

33	SEMINARS	Mércores IDIS	30
		IDIS talks	3
12	SYMPOSIA & CONFERENCES		
7	ONE SESSION SEMINARS		
4	INSTITUTIONAL INFORMATION SESSIONS		
110	TRAINING ACTIVITIES		
28	TOTAL OUTREACH ACTIVITIES	School visits	15
		Outreach activities	4
		Citizen engagement	7
		Fairs	2



07. TRAINING AND DISSEMINATION

Press & web

78057
WEB VISITS

PRESS RELEASES
ON IDIS WEBSITE

108

PRESS RELEASES
IN THE MEDIA

76

REPERCUSSIONS IN
WRITTEN PRESS

370




REPERCUSSIONS IN
AUDIOVISUAL PRESS

21



Social Networks

Followers



Outreach activities



IDIS is committed to science communication and public engagement. **In 2025, IDIS successfully completed its renewal process for the registration in the Network of Scientific Culture and Innovation Units (coordinated by FECYT).**

Through its Scientific Culture and Innovation Unit (UCC+i), IDIS promotes the visibility and understanding of its research, fosters scientific vocations and critical thinking, and develops outreach activities, social media engagement, and training in science communication.



TOTAL OUTREACH
ACTIVITIES 2025

28



15

School visits

Fairs



2

Citizen engagement



7



4

Other outreach activities



idis

HEALTH RESEARCH INSTITUTE, SANTIAGO DE COMPOSTELA

Strategic alliances

ANNUAL REPORT 2025

8

08. STRATEGIC ALLIANCES

TOTAL

5

RICORS



RICORS2040

Kidney Disease Network



RICORS ICTUS

Cerebrovascular Diseases Network



RICORS RIAPAd

Network of Research in Primary Care of Addictions



RICORS SAMID Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin



RICORS RICAPPS Research Network on Chronicity, Primary Care and Prevention and Health Promotion

TOTAL

3

IMPACT – Precision Medicine Associated with Science and Technology

IMPACT-Genómica

IMPACT-Cohorte

IMPACT-Data



IMPACT Genómica



IMPACT Cohorte



IMPACT Data

TOTAL

7

CIBER

ciber | **OBN****CIBEROBN**, Physiopathology of Obesity and Nutrition*ciber* | **ER****CIBERER**, Rare Diseases*ciber* | **ESP****CIBERESP**, Public Health and Epidemiology*ciber* | **CV****CIBERCV**, Cardiovascular Diseases*ciber* | **ONC****CIBERONC**, Cancer*ciber* | **NED****CIBERNED**, Neurodegenerative Diseases*ciber* | **ES****CIBERES**, Respiratory Diseases

08. STRATEGIC ALLIANCES

TOTAL

2

Platforms



Spanish
Clinical
Research
Network
ISCIII

SCREN

itemas isciii

Plataforma de dinamización e innovación de las capacidades
industriales del Sistema Nacional de Salud

ITEMAS

TOTAL

4

International network

eatris

EATRIS



European Cooperation in
Science and Technology

COST

eu:openscreen

EU OPENSREEN



ECRIN

TOTAL

6

Other networks



RECLIP



REGIC



CSG



BIOGA



REDTRANSFER



CERTERA



idis

HEALTH RESEARCH INSTITUTE, SANTIAGO DE COMPOSTELA



Areas

ANNUAL REPORT 2025



A001 ONCOLOGY

LEADER

RAFAEL LÓPEZ LÓPEZ / YOLANDA PREZADO ALONSO

AC01	Translational Hematology and Advanced Therapies	<i>Manuel Mateo Pérez Encinas</i>
AC06	Translational Ophthalmology	<i>María José Blanco Teijeiro</i>
AC08	Surgical Oncology	<i>Manuel Bustamante Montalvo</i>
C010	Genetics of Human Diseases	<i>Fernando Domínguez Puente</i>
C011	Pathology	<i>José Ramón Antúnez López</i>
C025	NANOBIOFAR	<i>María José Alonso Fernández</i>
C030	Translational Medical Oncology	<i>Rafael López López</i>
C032	Molecular Imaging	<i>Virginia Pubul Núñez</i> <i>Coleader: Pablo Aguiar Fernández</i>
C045	Cellular senescence, cancer and aging	<i>Manuel Collado Rodríguez</i>
C050	Mobile genomes and disease	<i>José Manuel Castro Tubío</i>
E004	Molecular Oncology	<i>José Antonio Costoya Puente</i>
E018	Cell Cycle and Oncology (CiClOn)	<i>Anxo Vidal Figueroa</i>
E031	Oncologic endocrinology	<i>Román Pérez Fernández</i>
E032	Preclinical Animal Models	<i>Laura Sánchez Piñón</i>
E033	Viruses and cancer	<i>María del Carmen Rivas Vázquez</i>
E037	DNA Repair and Genome Integrity	<i>Miguel González Blanco</i>
E043	Medical Physics and Biomathematics	<i>Juan Pardo Montero</i>
E044	Nano-Oncology and Translational Therapy Unit	<i>María de la Fuente Freire</i> <i>Coleader: Jenifer García Fernández</i>
E051	Oral and maxillofacial medical-surgical pathology (ORALRES)	<i>Mario Pérez-Sayáns García</i>
E060	Computational and genomic hematology (Grheco Xen)	<i>Adrián Mosquera Orgueira</i>
E064	New approaches in radiotherapy (NARA)	<i>Yolanda Prezado Alonso</i>



Personal and technical staff

285



213 Publications



18 Projects



28 Human Resources



80 Clinical Studies



25 PhD Theses

A002

GENETICS AND SYSTEMS BIOLOGY


LEADERS **ÁNGEL MARÍA CARRACEDO ÁLVAREZ / MARÍA ISABEL LOZA GARCÍA**

C005	Genetics	<i>Ángel María Carracedo Álvarez</i>
C009	Translational Research in Digestive System Diseases	<i>Juan Enrique Domínguez Muñoz Coleader: Yolanda Pazos Randulfe</i>
C026	BIOFARMA	<i>María Isabel Loza García</i>
C041	Genetics in Cancer and Rare Diseases	<i>Ana Paula Vega Gliemmo</i>
E012	Comparative Genomics of Human Parasites	<i>Julio Manuel Maside Rodríguez</i>
E020	Psychiatric Genetics	<i>Javier Costas Costas</i>
E021	Genetics and Developmental Biology of Kidney Diseases	<i>Miguel Ángel García González</i>
E035	Genetics of Gastrointestinal Tumours	<i>Clara Ruiz Ponte</i>
E036	Stem Cells and Human Diseases	<i>Miguel Ángel Fidalgo Pérez</i>
E047	Cancer Genetics and Epidemiology Group	<i>Manuela Gago Domínguez</i>
E054	Epitranscriptomics and aging	<i>Diana Guallar Artal</i>
E055	Cancer predisposition and biomarkers	<i>Ceres Fernández Rozadilla</i>
E059	MitoPhenomics	<i>Aurora Gómez Durán</i>
E061	Pharmacogenomics and drug discovery (GenDeM)	<i>Olalla Maroñas Amigo</i>
E068	Inmunogenetics	<i>Roberto Díaz Peña</i>



Personal and technical staff

201



186 Publications



21 Projects



6 Human Resources



42 Clinical Studies



8 PhD Theses

A003 ENDOCRINOLOGY, NUTRITION AND METABOLISM

LEADERS

MIGUEL ÁNGEL MARTÍNEZ OLMOS / LUISA MARÍA SEOANE CAMINO

AC04	Paediatric Endocrinology	<i>Lidia Castro Feijoo</i>
C001	Neoplasia and Endocrine Differentiation	<i>Clara Álvarez Villamarín</i>
C006	Molecular Endocrinology	<i>Miguel Ángel Martínez Olmos</i>
C008	Obesity and Nutrition	<i>Carlos Diéguez González</i>
C012	Metabolic disorders	<i>María Luz Couce Pico</i>
C019	Thyroid and Metabolic Diseases Unit (UETeM)	<i>David Araújo Vilar</i>
C022	Paediatric Nutrition	<i>Rosaura Leis Trabazo</i>
C029	Neurobesity	<i>Miguel López Pérez</i>
C031	Molecular Metabolism	<i>Rubén Nogueiras Pozo</i>
C037	Trace Elements, Spectroscopy and Speciation	<i>Pilar Bermejo Barrera</i>
E023	Obesidomics	<i>María Pardo Pérez</i>
E025	Myology	<i>Jesús Pérez Camiña</i>
E026	Endocrine Physiopathology	<i>Luisa María Seoane Camino</i>
E039	Diabesity	<i>Sulay Tovar Carro</i>
E041	Epigenomics in Endocrinology and Nutrition	<i>Ana Belén Crujeiras Martínez</i>
E057	Translational Endocrinology	<i>Omar Al-Massadi Iglesias</i>
E062	Immunology and small molecules	<i>Iria Gómez Touriño</i>
E063	Neuroendocrine Regulation of Metabolism (NeuRoMet)	<i>Ismael González García</i>



Personal and
technical staff

165



146 Publications



14 Projects



9 Human
Resources



11 Clinical
Studies



10 PhD
Theses

A004

NEUROSCIENCES

LEADERS


JOSÉ LUIS LABANDEIRA GARCÍA / FRANCISCO CAMPOS PÉREZ

AC03	Critical Patient	<i> Julián Álvarez Escudero</i>
AC27	Neuroradiology	<i> Antonio Jesús Mosqueira Martínez</i>
C015	Neurobiology of the Visual System	<i> Francisco González García</i>
C018	Experimental Neurology of Parkinson's Disease	<i> José Luis Labandeira García</i>
C033	Design, Synthesis and Medical Evaluation of Bioactive Compounds and New Materials	<i> Antonio Mouriño Mosquera</i>
C034	Physics of Polymers and Colloids	<i> Sílvia Barbosa Fernández</i>
C035	R&D in Drugs Dose Forms and Delivery Systems	<i> Carmen Álvarez Lorenzo</i>
C036	Magnetism and Nanotechnology (NanoMag)	<i> José Rivas Rey</i>
C038	Analytical Chemistry of Compounds of Alimentary, Environmental and Biological Interest	<i> Antonia María Carro Díaz</i>
C042	Translational Stroke	<i> Francisco Campos Pérez</i>
C043	Neuroimaging and Biotechnology	<i> Ramón Iglesias Rey</i>
C044	Neuroaging	<i> Tomás Sobrino Moreiras</i>
C046	Gene Regulatory Control in Disease (GeneRegulon)	<i> Ashwin Woodhoo</i>
E014	Prion Diseases	<i> Jesús Rodríguez Requena</i>
E019	Cell Stress	<i> Juan Bautista Zalvide Torrente</i>
E029	Cognitive Neuroscience	<i> Fernando Díaz Fernández</i>
E050	Headaches and Craniofacial Pain	<i> Rogelio Leira Muíño</i>
E052	Corneal neurodegeneration	<i> María Isabel Lema Gesto Coleader: Uxia Regueiro Lorenzo</i>
E053	Circadian and Glial Biology (GLIATIME)	<i> Olga Barca Mayo</i>
E065	Translational Research in Neurological Diseases (ITEN)	<i> José María Prieto González Coleader: Roberto Carlos Agís Balboa</i>
E067	Brain plasticity	<i> Alba Vieites Prado</i>



Personal and
technical staff

253



217 Publications



20 Projects



19 Human
Resources



22 Clinical
Studies



21 PhD
Theses

A005

PLATFORMS AND METHODOLOGY


LEADERS **FRANCISCO GUDE SAMPEDRO / IRENE ZARRA FERRO**

AC10	Healthy ageing, fragility and chronicity. Research in Primary Care	<i>Juán Manuel Vázquez Lago</i>
AC13	Dermatology and Craniofacial Pathology (DePaCra)	<i>Pablo Ignacio Varela Centelles</i>
AC21	Pharmacological Biochemistry	<i>Fernando Jesús Hermida Ameijeiras</i>
AC23	Nursing, Management and Care	<i>Sandra Vidal Martínez</i>
AC24	Optometry	<i>Eva Yebra-Pimentel Vilar</i>
AC25	Radiology	<i>Miguel Souto Bayarri</i>
AC26	Experimental and reconstructive maxillofacial microsurgery (MERMEX)	<i>Joaquim Megías Barrera</i>
AC28	Home hospitalization and Telemedicine	<i>Ignacio Novo Veleiro</i>
C002	Surgery: Complications and Advances	<i>Miguel Ángel Caínzos Fernández</i>
C013	Epidemiology, Public Health and Evaluation of Health Services	<i>Adolfo Figueiras Guzmán</i>
C017	Research methodology	<i>Francisco Gude Sampedro</i> <i>Coleader: Manuela Alonso Sampedro</i>
C021	Clinical Analysis	<i>Santiago Rodríguez-Segade Villamarín</i>
E034	FarmaCHUSLab	<i>Anxo Fernández Ferreiro</i>
E046	PARAQUASIL	<i>Francisco Javier Otero Espinar</i>
E058	Oral Sciences (OSRG)	<i>Benjamín Martín Biedma</i>



Personal and
technical staff

185



238 Publications



16 Projects



3 Human
Resources



6 Clinical
Studies



21 PhD
Theses

A006

CARDIOVASCULAR


LEADERS **JOSÉ RAMÓN GONZÁLEZ JUANATEY / MOISÉS RODRÍGUEZ MAÑERO**

AC05	Pneumology	<i>Luis Guillermo Valdés Cuadrado</i>
AC07	Semergal	<i>Sergio Cinza Sanjurjo</i>
AC19	Vascular Research Group of Santiago (VARGROS)	<i>Diego Caicedo Valdés</i>
C003	Hypertension	<i>Antonio Posé Reino</i> <i>Coleader: Álvaro Hermida Ameijeiras</i>
C016	Cardiology	<i>José Ramón González Juanatey</i>
C027	Neuroendocrine Interactions in Rheumatic and Inflammatory Diseases (Neirid)	<i>Oreste Gualillo</i>
C039	Biodiscovery	<i>Luis Miguel Botana Pérez</i> <i>Coleader: María Amparo Alfonso Rancaño</i>
C048	Cardiovascular Genetics	<i>María José Brión Martínez</i>
E009	Cellular and Molecular Cardiology	<i>Francisca Lago Paz</i> <i>Coleader: Alana Aragón Herrera</i>
E030	Platelet Proteomics	<i>Ángel García Alonso</i>
E045	Translational Cardiology	<i>Sonia Eiras Penas</i> <i>Coleader: Moisés Rodríguez Mañero</i>
E056	Metabolic homeostasis and vascular calcification	<i>Ricardo Villa Bellosta</i>



Personal and technical staff

174



165 Publications



12 Projects



5 Human Resources



57 Clinical Studies



8 PhD Theses

A007 INFECTOLOGY, INFLAMMATION AND VACCINES

LEADERS **FEDERICO MARTINÓN TORRES / RODOLFO GÓMEZ BAHAMONDE**

AC20	Translational Research of Airway Diseases	<i>Francisco Javier González Barcala Coleader: Francisco Javier Salgado Castro</i>
C014	Rheumatology	<i>Eva María Pérez Pampín</i>
C020	Genetics, Vaccines, Infections & Pediatrics (GENVIP)	<i>Federico Martinón Torres Coleader: Irene Rivero Calle</i>
C028	Experimental and Observational Rheumatology	<i>Antonio González Martínez-Pedrayo</i>
C040	Medical-Surgical Dentistry (OMEQUI)	<i>Pedro Diz Dios</i>
C047	Population Genetics in Biomedicine (GenPoB)	<i>Antonio Salas Ellacuriaga Coleader: Alberto Gómez Carballa</i>
E013	Microbiology	<i>María Luisa Pérez del Molino Bernal</i>
E027	Escherichia coli	<i>Jorge Blanco Álvarez</i>
E038	Musculoskeletal Pathology	<i>Rodolfo Gómez Bahamonde</i>
E048	Molecular and Cellular Gastroenterology	<i>Javier Conde Aranda</i>
E066	Simulation, Life Support and Intensive Care (SICRUS)	<i>Antonio Rodríguez Núñez</i>



Personal and
technical staff

184



208 Publications



13 Projects



7 Human
Resources



44 Clinical
Studies



15 PhD
Theses

idisantiago.es

ANNUAL REPORT 2025





XUNTA
DE GALICIA

CONSELLERÍA
DE SANIDADE

Xacobeo  2027



ANNUAL REPORT 2025

INSTITUTO DE INVESTIGACIÓN SANITARIA
SANTIAGO DE COMPOSTELA